Literature DB >> 24423358

The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition.

Mary H Samuels1, Irina Kolobova, Anne Smeraglio, Dawn Peters, Jeri S Janowsky, Kathryn G Schuff.   

Abstract

CONTEXT: TSH-suppressive doses of levothyroxine (L-T4) have adverse effects on bone and cardiac function, but it is unclear whether central nervous system function is also affected.
OBJECTIVE: The aim of the study was to determine whether women receiving TSH-suppressive L-T4 doses have decrements in health status, mood, or cognitive function. DESIGN AND
SETTING: A cross-sectional comparison was made among three groups of women in an academic medical center research clinic. PATIENTS: Twenty-four women receiving chronic TSH-suppressive L-T4 doses, 35 women receiving chronic replacement L-T4 doses, and 20 untreated control women participated in the study.
INTERVENTIONS: Subjects underwent testing at a single outpatient visit. MAIN OUTCOME MEASURES: We measured health status (SF-36), mood (Profile of Mood States, Symptom Checklist 90-R, Affective Lability Scale), and cognitive function (declarative memory [Paragraph Recall], working memory [N-back, Subject Ordered Pointing], motor learning [Pursuit Rotor, Motor Sequence Learning Test], and executive function [Letter Cancellation Test, Trail Making Test, Iowa Gambling Test]).
RESULTS: Women receiving TSH-suppressive or replacement L-T4 doses had decrements in health status and mood compared to healthy controls. These decrements were more pronounced in women receiving replacement, rather than suppressive, L-T4 doses. Memory and executive function were not affected in either treated group, compared to healthy controls.
CONCLUSIONS: Women receiving TSH-suppressive doses of L-T4 do not have central nervous system dysfunction due to exogenous subclinical thyrotoxicosis, but TSH-suppressed and L-T4-replaced women have slight decrements in health status and mood that may be related to self-knowledge of the presence of a thyroid condition or other uncharacterized factors. These mood alterations do not impair cognitive function.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24423358      PMCID: PMC3942231          DOI: 10.1210/jc.2013-3686

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients.

Authors:  B Biondi; E A Palmieri; S Fazio; C Cosco; M Nocera; L Saccà; S Filetti; G Lombardi; F Perticone
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

Review 2.  Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism?

Authors:  Bernadette Biondi; Leonard Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  2012-05-16       Impact factor: 5.958

3.  Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma.

Authors:  J Jaracz; A Kucharska; A Rajewska-Rager; K Lacka
Journal:  J Endocrinol Invest       Date:  2011-10-06       Impact factor: 4.256

4.  Thyroid hormones and depression: the Health in Men study.

Authors:  Osvaldo P Almeida; Helman Alfonso; Leon Flicker; Graeme Hankey; S A Paul Chubb; Bu B Yeap
Journal:  Am J Geriatr Psychiatry       Date:  2011-09       Impact factor: 4.105

Review 5.  Structural and functional alterations in the hippocampus due to hypothyroidism.

Authors:  Christos Koromilas; Charis Liapi; Kleopatra H Schulpis; Konstantinos Kalafatakis; Apostolos Zarros; Stylianos Tsakiris
Journal:  Metab Brain Dis       Date:  2010-10-01       Impact factor: 3.584

6.  An association between depression, anxiety and thyroid function--a clinical fact or an artefact?

Authors:  Anne Engum; Trine Bjøro; Arnstein Mykletun; Alv A Dahl
Journal:  Acta Psychiatr Scand       Date:  2002-07       Impact factor: 6.392

7.  Is there a relationship between fatigue perception and the serum levels of thyrotropin and free thyroxine in euthyroid subjects?

Authors:  Annenienke C van de Ven; Romana T Netea-Maier; Femmie de Vegt; H Alec Ross; Fred C G J Sweep; Lambertus A Kiemeney; Ad R Hermus; Martin den Heijer
Journal:  Thyroid       Date:  2012-10-19       Impact factor: 6.568

8.  Health-related quality of life in patients with thyroid disorders.

Authors:  G P Bianchi; V Zaccheroni; E Solaroli; F Vescini; R Cerutti; M Zoli; G Marchesini
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

9.  Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.

Authors:  J I Botella-Carretero; J M Galán; C Caballero; J Sancho; H F Escobar-Morreale
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

10.  Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study.

Authors:  P Saravanan; W-F Chau; N Roberts; K Vedhara; R Greenwood; C M Dayan
Journal:  Clin Endocrinol (Oxf)       Date:  2002-11       Impact factor: 3.478

View more
  8 in total

1.  An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction.

Authors:  Sarah J Peterson; Anne R Cappola; M Regina Castro; Colin M Dayan; Alan P Farwell; James V Hennessey; Peter A Kopp; Douglas S Ross; Mary H Samuels; Anna M Sawka; Peter N Taylor; Jacqueline Jonklaas; Antonio C Bianco
Journal:  Thyroid       Date:  2018-04-05       Impact factor: 6.568

Review 2.  Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis.

Authors:  Omar Saeed; Lori J Bernstein; Rouhi Fazelzad; Mary Samuels; Lynn A Burmeister; Lehana Thabane; Shereen Ezzat; David P Goldstein; Jennifer Jones; Anna M Sawka
Journal:  J Cancer Surviv       Date:  2019-04-04       Impact factor: 4.442

Review 3.  Psychiatric and cognitive manifestations of hypothyroidism.

Authors:  Mary H Samuels
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

4.  Cognitive impairment in women newly diagnosed with thyroid cancer before treatment.

Authors:  Mi Sook Jung; Moira Visovatti; Mijung Kim; Kyengin Cha; Nondumiso Dlamini; Xirong Cui
Journal:  Support Care Cancer       Date:  2022-08-03       Impact factor: 3.359

5.  Effect of Thyroid Function Variations Within the Laboratory Reference Range on Health Status, Mood, and Cognition in Levothyroxine-Treated Subjects.

Authors:  Mary H Samuels; Irina Kolobova; Anne Smeraglio; Meike Niederhausen; Jeri S Janowsky; Kathryn G Schuff
Journal:  Thyroid       Date:  2016-07-25       Impact factor: 6.568

6.  Hypothyroidism and its rapid correction alter cardiac remodeling.

Authors:  Georges Hajje; Youakim Saliba; Tarek Itani; Majed Moubarak; Georges Aftimos; Nassim Farès
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

7.  Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma.

Authors:  Ruihua Wang; Liu Yang; Shui Jin; Xingmin Han; Baoping Liu
Journal:  Cancer Cell Int       Date:  2018-11-19       Impact factor: 5.722

Review 8.  What Is the Quality of Life in Patients Treated with Levothyroxine for Hypothyroidism and How Are We Measuring It? A Critical, Narrative Review.

Authors:  Françoise Borson-Chazot; Jean-Louis Terra; Bernard Goichot; Philippe Caron
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.